Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Small Cell Lung Carcinoma × Cyclophosphamide × Clear all

Phase

Phase 1 4 Phase EARLY_PHASE1 2 Phase 2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 132 Lymphoma 54 Precursor Cell Lymphoblastic Leukemia-Lymphoma 44 Lymphoma, Large B-Cell, Diffuse 43 Leukemia 41 Lymphoma, Follicular 36 Lymphoma, Non-Hodgkin 32 Multiple Myeloma 29 Leukemia, Lymphocytic, Chronic, B-Cell 25 Leukemia, Myeloid, Acute 23 Burkitt Lymphoma 23 Neuroblastoma 20 Hodgkin Disease 16 Lymphoma, Large-Cell, Immunoblastic 15 Neoplasms 12 Lymphoma, Mantle-Cell 12 Lymphoma, B-Cell, Marginal Zone 10 Triple Negative Breast Neoplasms 9 Sarcoma 8 Neoplasms, Plasma Cell 8 Myelodysplastic Syndromes 8 Inflammatory Breast Neoplasms 8 Graft vs Host Disease 8 Rhabdomyosarcoma 7 Recurrence 7 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7 Lymphoma, T-Cell, Peripheral 6 Lymphoma, Large-Cell, Anaplastic 6 Lung Neoplasms 6 Leukemia, Erythroblastic, Acute 5

Interventions

Etoposide 30 Carboplatin 28 Cisplatin 20 Topotecan 19 atezolizumab 9 durvalumab 7 PM 01183 6 Irinotecan 5 amrubicin 4 AMG 757 4 rovalpituzumab tesirine 3 PE regimen 3 Dexamethasone 3 tremelimumab 2 pembrolizumab 2 etoposide phosphate 2 apatinib 2 Vitamin E 2 Tiragolumab 2 RRx-001 2 Magnetic Resonance Spectroscopy 2 trilaciclib 1 toripalimab 1 tislelizumab 1 racotumomab 1 olaparib 1 obatoclax 1 marimastat 1 isophosphamide mustard 1 irinotecan sucrosofate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02566993 2021-10-28

ATLANTIS

PharmaMar

Phase 3 Completed

613 enrolled 46 charts

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡